Candesartan cilexetil/chlortalidone

Drug Profile

Candesartan cilexetil/chlortalidone

Alternative Names: Candesartan/chlortalidone; Chlortalidone/candesartan; Chlortalidone/candesartan-cilexetil

Latest Information Update: 01 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EMS
  • Class Antihypertensives; Benzimidazoles; Small molecules; Sulfonamides; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Thiazide-like diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Essential hypertension

Most Recent Events

  • 17 Jan 2017 EMS withdraws a phase III trial before enrolment due to sponsor decision for Essential hypertension in Brazil (NCT02521233)
  • 19 Aug 2015 Preclinical trials in Essential hypertension in Brazil (PO)
  • 19 Aug 2015 EMS plans a phase III trial for Essential hypertension in Brazil (NCT02521233)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top